L O A D I N G
December 12, 2019

The Column Group Raises a $725 Million Fourth Fund

SAN FRANCISCO – The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, the firm will continue to execute on the strategy it has deployed since inception – assembling a focused portfolio of “big idea” companies, each built from the ground up with platforms capable of generating multiple differentiated product opportunities. To date, TCG has raised $2.2 billion. “We are grateful for the strong support for our model and are pleased by the significant interest generated from our existing investors, with room for a handful of new investors,” said Peter Svennilson, Founder and Managing Partner of The Column Group. “Since 2007, TCG has been dedicated to early stage drug discovery investing as a compelling path to value creation driven by the advancement of new, highly effective human therapies that can change the world. We believe that focus is critical and we will continue to deploy a hands-on approach to building a small cohort of high quality, science-driven companies for our fourth fund.”

About The Column Group
The Column Group is a leading venture capital firm based in San Francisco that seeks to partner with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in disease-focused drug discovery companies with the potential to become leaders in their respective fields. These companies are strongly supported by the unique and complementary skill sets of TCG’s team, which includes prominent authorities in the scientific, operational, and financial arenas.

For more information, please visit www.thecolumngroup.com.

Select Portfolio Companies of The Column Group
NGM Biopharmaceuticals, Constellation Pharmaceuticals, Immune Design (acquired by Merck in 2019), Aragon Pharmaceuticals (acquired by Johnson & Johnson in 2013), Carmot Therapeutics, Peloton Therapeutics (acquired by Merck in 2019), Nurix, Seragon Pharmaceuticals (acquired by Roche in 2014), Flexus Biosciences (acquired by Bristol Myers Squibb in 2015), eFFECTOR Therapeutics, ORIC Pharmaceuticals, Neurona Therapeutics, RAPT Therapeutics (formerly FLX Bio), Arcus Biosciences, Gritstone Oncology, Kallyope, Ribon Therapeutics, Surrozen, Tenaya Therapeutics, Revolution Medicines, Accent Therapeutics, Exonics Therapeutics (acquired by Vertex in 2019), A2 Biotherapeutics, Proneurotech, Escient Pharmaceuticals, Synthekine, and Plexium.